Cargando…
Dexamethasone versus weight-adjusted methylprednisolone in patients with moderate-severe SARS-CoV-2 pneumonia
OBJECTIVES: To compare the 30-day outcome (mortality and/or ICU admission) of patients admitted for moderate-severe SARS-CoV-2 pneumonia treated with dexamethasone after the Recovery study versus those treated with weight-adjusted methylprednisolone. METHODS: Retrospective cohort study of 65 patient...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier España, S.L.U.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9870753/ https://www.ncbi.nlm.nih.gov/pubmed/36713976 http://dx.doi.org/10.1016/j.medcle.2023.01.002 |
_version_ | 1784877035244486656 |
---|---|
author | Aomar-Millán, Ismael F. Fatoul-del Pino, Geoorgette Torres-Parejo, Úrsula Pérez Fernández, Laura Martínez-Diz, Silvia Salvatierra, Juan |
author_facet | Aomar-Millán, Ismael F. Fatoul-del Pino, Geoorgette Torres-Parejo, Úrsula Pérez Fernández, Laura Martínez-Diz, Silvia Salvatierra, Juan |
author_sort | Aomar-Millán, Ismael F. |
collection | PubMed |
description | OBJECTIVES: To compare the 30-day outcome (mortality and/or ICU admission) of patients admitted for moderate-severe SARS-CoV-2 pneumonia treated with dexamethasone after the Recovery study versus those treated with weight-adjusted methylprednisolone. METHODS: Retrospective cohort study of 65 patients with moderate-severe pneumonia who received dexamethasone 6 mg/day (DXM group) versus 80 treated with weight-adjusted methylprednisolone (MTPN group) RESULTS: 21 (32.3%) patients in the DXM group died vs 8 (10%) in the MTPN group (p-value < 0.001) and 29 (44.6%) in the DXM group required ICU admission vs 2 (2,5%) of the MTPN group (p-value <0.001). There were no baseline differences regarding sociodemographic characteristics with a higher mean qSOFA in the MTPN group. The hazard ratio for mortality and ICU admission adjusted for age, sex, and admission CRP was 2.189 (1.082–4.426; 95% CI) and 10.589 (2.139–48.347; 95% CI) for the DXM group, respectively, vs. MTPN group. CONCLUSIONS: Mortality and admission to the ICU were lower in patients treated with weight-adjusted methylprednisolone compared to those treated with dexamethasone. |
format | Online Article Text |
id | pubmed-9870753 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Elsevier España, S.L.U. |
record_format | MEDLINE/PubMed |
spelling | pubmed-98707532023-01-25 Dexamethasone versus weight-adjusted methylprednisolone in patients with moderate-severe SARS-CoV-2 pneumonia Aomar-Millán, Ismael F. Fatoul-del Pino, Geoorgette Torres-Parejo, Úrsula Pérez Fernández, Laura Martínez-Diz, Silvia Salvatierra, Juan Med Clin (Engl Ed) Brief Report OBJECTIVES: To compare the 30-day outcome (mortality and/or ICU admission) of patients admitted for moderate-severe SARS-CoV-2 pneumonia treated with dexamethasone after the Recovery study versus those treated with weight-adjusted methylprednisolone. METHODS: Retrospective cohort study of 65 patients with moderate-severe pneumonia who received dexamethasone 6 mg/day (DXM group) versus 80 treated with weight-adjusted methylprednisolone (MTPN group) RESULTS: 21 (32.3%) patients in the DXM group died vs 8 (10%) in the MTPN group (p-value < 0.001) and 29 (44.6%) in the DXM group required ICU admission vs 2 (2,5%) of the MTPN group (p-value <0.001). There were no baseline differences regarding sociodemographic characteristics with a higher mean qSOFA in the MTPN group. The hazard ratio for mortality and ICU admission adjusted for age, sex, and admission CRP was 2.189 (1.082–4.426; 95% CI) and 10.589 (2.139–48.347; 95% CI) for the DXM group, respectively, vs. MTPN group. CONCLUSIONS: Mortality and admission to the ICU were lower in patients treated with weight-adjusted methylprednisolone compared to those treated with dexamethasone. Elsevier España, S.L.U. 2023-02-24 2023-01-24 /pmc/articles/PMC9870753/ /pubmed/36713976 http://dx.doi.org/10.1016/j.medcle.2023.01.002 Text en © 2022 Elsevier España, S.L.U. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Brief Report Aomar-Millán, Ismael F. Fatoul-del Pino, Geoorgette Torres-Parejo, Úrsula Pérez Fernández, Laura Martínez-Diz, Silvia Salvatierra, Juan Dexamethasone versus weight-adjusted methylprednisolone in patients with moderate-severe SARS-CoV-2 pneumonia |
title | Dexamethasone versus weight-adjusted methylprednisolone in patients with moderate-severe SARS-CoV-2 pneumonia |
title_full | Dexamethasone versus weight-adjusted methylprednisolone in patients with moderate-severe SARS-CoV-2 pneumonia |
title_fullStr | Dexamethasone versus weight-adjusted methylprednisolone in patients with moderate-severe SARS-CoV-2 pneumonia |
title_full_unstemmed | Dexamethasone versus weight-adjusted methylprednisolone in patients with moderate-severe SARS-CoV-2 pneumonia |
title_short | Dexamethasone versus weight-adjusted methylprednisolone in patients with moderate-severe SARS-CoV-2 pneumonia |
title_sort | dexamethasone versus weight-adjusted methylprednisolone in patients with moderate-severe sars-cov-2 pneumonia |
topic | Brief Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9870753/ https://www.ncbi.nlm.nih.gov/pubmed/36713976 http://dx.doi.org/10.1016/j.medcle.2023.01.002 |
work_keys_str_mv | AT aomarmillanismaelf dexamethasoneversusweightadjustedmethylprednisoloneinpatientswithmoderateseveresarscov2pneumonia AT fatouldelpinogeoorgette dexamethasoneversusweightadjustedmethylprednisoloneinpatientswithmoderateseveresarscov2pneumonia AT torresparejoursula dexamethasoneversusweightadjustedmethylprednisoloneinpatientswithmoderateseveresarscov2pneumonia AT perezfernandezlaura dexamethasoneversusweightadjustedmethylprednisoloneinpatientswithmoderateseveresarscov2pneumonia AT martinezdizsilvia dexamethasoneversusweightadjustedmethylprednisoloneinpatientswithmoderateseveresarscov2pneumonia AT salvatierrajuan dexamethasoneversusweightadjustedmethylprednisoloneinpatientswithmoderateseveresarscov2pneumonia |